KYMR FY2025 SEC EDGAR DEF 14A #125 of 168 in industry

Kymera Therapeutics, Inc. CEO pay ratio

The CEO earned $8.6M in FY2025 against median worker pay of $409,607 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-29
Industry
Chemicals & Pharmaceuticals
Industry rank
#125/168

Data updated August 2026

Subscribe to Kymera Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
21:1
Below Average (Scale: 0–1000:1)
CEO pay
$8.6M
Median worker
$409,607

Answer first

Kymera Therapeutics, Inc.'s FY2025 CEO total of $8.6M ranks #628 of 1,423 complete filings; its 21:1 pay ratio ranks #1207. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $409,607. Industry placement uses the FY2025 SIC-28 peer cohort (# 125 of 168, 26th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#628
$8.6M of 1,423 FY2025
Ratio rank
#1207
21:1 of 1,423
Industry pct
26th
below the industry median pay ratio

How Kymera Therapeutics, Inc. ranks nationally

Kymera Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$8,601,747 Top 44% higher than 56% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Kymera Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($8.6M) against pay ratio (21:1) for Kymera Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02253862.04507724.16761586.19015448.217.9:124.2:130.5:136.8:143.1:1CEO total payPay ratio (CEO : median worker)Kymera Therapeutics, Inc., CEO total pay: 8601747 · Pay ratio (CEO : median worker): 21:1Kymera Therapeutics, Inc.Akebia Therapeutics, Inc., CEO total pay: 5652339 · Pay ratio (CEO : median worker): 21:1Akebia Therapeutics, Inc.Nuvalent, Inc., CEO total pay: 540474 · Pay ratio (CEO : median worker): 21:1Nuvalent, Inc.Arvinas, Inc., CEO total pay: 327724 · Pay ratio (CEO : median worker): 20:1Arvinas, Inc.Kronos Worldwide Inc, CEO total pay: 2256576 · Pay ratio (CEO : median worker): 23:1Kronos Worldwide IncSyndax Pharmaceuticals Inc, CEO total pay: 7281788 · Pay ratio (CEO : median worker): 19:1Syndax Pharmaceuticals Inc
Kymera Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Kymera Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Kymera Therapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
21:1
FY2025
vs prior FY
-18:1
from FY2024 39:1
CEO $ YoY
-44%
$8.6M latest
Filings shown
4
FY2022–2025
Kymera Therapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $6.8M - $341,869 20:1 -
2023 $9.8M +44% $516,701 19:1 -1:1
2024 $15.4M +57% $395,052 39:1 +20:1
2025 $8.6M -44% $409,607 21:1 -18:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1815442, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
21:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$8.6M
Companies in Industry
168
vs. Industry Median
Below
#125 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Kymera Therapeutics, Inc.: near-parity Item 402(u) ratio

Kymera Therapeutics, Inc.'s FY2025 ratio 21:1 ranks #125 of 168 Chemicals & Pharmaceuticals filers (26th percentile). the CEO earned 21× the median employee ($409,607) in FY2025.

At $409,607 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$8.6M

FY2025 Summary Compensation, near median

Pay Ratio

21:1

Below typical

Kymera Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Kymera Therapeutics, Inc.'s FY2025 ratio 21:1 ranks #125 of 168 Chemicals & Pharmaceuticals filers (26th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Kymera Therapeutics, Inc.'s $8.6M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #628 and ratio rank #1207 split - treat 21:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$8.6M
Median Employee Pay
$409,607
Pay Ratio
21:1
Filing Date
2026-04-29

Company Info

Ticker
KYMR
CIK
1815442
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1815442, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Kymera Therapeutics, Inc.'s FY2025 ratio 21:1 ranks #125 of 168 Chemicals & Pharmaceuticals filers (26th percentile).

Read with Kymera Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

Chemours Co · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $1K lighter vs Kymera Therapeutics, Inc.); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Alphatec Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $4K heavier vs Kymera Therapeutics, Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Stanley Black & Decker, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $23K lighter vs Kymera Therapeutics, Inc.); STEEP · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Cerence Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $25K lighter vs Kymera Therapeutics, Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Akebia Therapeutics, Inc. (SIC 28 pole)

Akebia Therapeutics, Inc. stamps FLOOR · MID$ nearest in-SIC by ABS(pay_ratio) to Kymera Therapeutics, Inc.'s FLOOR filing.
National dual ranks · #628/#1207

Kymera Therapeutics, Inc.'s FY2025 package sits #628 by CEO dollars and #1207 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Kymera Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Kymera Therapeutics, Inc. (CIK 1815442), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.